CHICAGO, Aug. 1, 2024
/PRNewswire/ -- The Association for Diagnostics &
Laboratory Medicine (ADLM, formerly AACC), welcomed thousands of
laboratory experts to ADLM 2024 (formerly the AACC Annual
Scientific Meeting & Clinical Lab Expo) from July 28-August 1. The meeting featured
groundbreaking advances in diagnostic research and technology that
exemplify the essential role that the field of laboratory medicine
plays in patient care.
As of Thursday, August 1, 18,000
laboratory medicine professionals had registered for ADLM 2024, a
6% increase in attendance since the last time the ADLM Annual
Meeting was in Chicago in 2022.
More attendees are expected today, the last day of the meeting.
One highlight of the meeting was a special session where
representatives from ADLM, the American Medical Association, and
the Children's Hospital Association detailed how the FDA's final
rule placing laboratory developed tests under FDA oversight will
negatively impact patient care. The session featured a caregiver
and patient advocate who shared her perspective on why laboratory
developed tests are crucial to timely diagnoses and treatment.
Attendees also had the opportunity to see five plenary talks led
by life sciences pioneers.
In the opening plenary, Dr. Patrick
Bossuyt — the 2024 Wallace H. Coulter Lectureship awardee —
drew on his experiences leading efforts to improve diagnostic tests
to make a compelling case for why we need strong clinical trials of
laboratory tests.
On Monday, Dr. Kojo S.J. Elenitoba-Johnson, chair of the
department of pathology and laboratory medicine at Memorial Sloan
Kettering Cancer Center, described how proteomic data can help
healthcare professionals better understand how lymphomas form and
drive development of precision oncology therapies.
Tuesday's plenary speaker, Dr. Ron H.N.
van Schaik, discussed the successes and challenges of
implementing pharmacogenetics as a diagnostic tool in routine
healthcare. Van Schaik is head of
the department of clinical chemistry at Erasmus MC - University
Medical Center Rotterdam.
On Wednesday, Dr. Sharon Hillier,
a professor at the University of
Pittsburgh, explored the development of new products for HIV
prevention, including those that can be used on demand and those
that would minimize systemic exposure to antiretroviral drugs.
In today's closing keynote, Dr. Diana
Greene Foster, a professor at the University of California, San Francisco, discussed
the mental health, physical health, and socioeconomic consequences
affecting people who are unable to get an abortion.
As part of ADLM's Disruptive Technology Award competition,
biotech innovators presented novel technologies that could help
more patients get accurate diagnoses. Mercy BioAnalytics won the
competition with its liquid biopsy platform that detects ovarian
cancer in its earliest stages by measuring tumor-derived
extracellular vesicles.
The ADLM 2024 Clinical Lab Expo boasted nearly 900 exhibitors
and covered an astonishing 271,003 net square feet — a 5% increase
in exhibit space since the last time the meeting was held in
Chicago. This dynamic exhibit
featured cutting-edge tests from all laboratory medicine
disciplines, including artificial intelligence, molecular
diagnostics, automation, point-of-care testing, mass spectrometry,
mobile health, and much more.
"We are thrilled to see attendance at ADLM 2024 continue to
increase after the COVID-19 pandemic," said ADLM CEO Mark J. Golden. "With the FDA publishing its
final rule on laboratory developed tests, this has been a
challenging year for laboratory medicine professionals. The meeting
provided a vital opportunity for attendees to learn more about what
the rule means for their labs and patient care. Additionally, the
meeting offered essential education on everything from lab basics
to cutting-edge topics such as data science. I hope attendees
return home inspired and eager to implement what they've learned
this week in their work, and I am excited to see what next year's
meeting will bring."
ADLM 2025 will be held in Chicago from July
27-31, 2025.
About ADLM 2024
ADLM 2024 (formerly the AACC Annual Scientific Meeting &
Clinical Lab Expo) offered 5 days packed with opportunities to
learn about exciting science from July
28-August 1 in Chicago.
Plenary sessions explored the projected consequences of ending
abortion protection, new HIV prevention options, lymphoma
biomarkers and therapeutic targets, pharmacogenetic testing in
precision health, and the need for clinical trials of laboratory
tests.
At the ADLM 2024 Clinical Lab Expo, nearly 900 exhibitors filled
the show floor of the McCormick Place Convention Center in
Chicago, with displays of the
latest diagnostic technology, including but not limited to
artificial intelligence, point-of-care testing, and automation.
About the Association for Diagnostics & Laboratory
Medicine (ADLM)
Dedicated to achieving better health through laboratory
medicine, ADLM (formerly AACC) brings together more than 70,000
clinical laboratory professionals, physicians, research scientists,
and business leaders from around the world focused on clinical
chemistry, molecular diagnostics, mass spectrometry, translational
medicine, lab management, and other areas of progressing laboratory
science. Since 1948, ADLM has worked to advance the common
interests of the field, providing programs that advance scientific
collaboration, knowledge, expertise, and innovation. For more
information, visit www.myadlm.org.
Christine DeLong
ADLM
Associate Director, Communications & PR
(p) 202.835.8722
cdelong@myadlm.org
Molly Polen
ADLM
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
mpolen@myadlm.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/expert-insights-on-laboratory-developed-tests-the-consequences-of-ending-abortion-protection-health-equity-and-more-draw-18-000-attendees-to-adlm-2024--302212611.html
SOURCE Association for Diagnostics & Laboratory Medicine
(ADLM)